Showing 1 - 17 results of 17 for search 'PHARMACOECONOMICS', query time: 0.28s Refine Results
  1. 1
    Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
    “... importance due to high morbidity and mortality. The goal of the study is pharmacoeconomic assessment of first...”
    Get full text
    Article
  2. 2
    Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis
    by A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova
    Published 2021-07-01
    Get full text
    Article
  3. 3
    PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY
    by A. V. Rudakova, S. A. Protsenko, I. A. Koroleva
    Published 2017-08-01
    Get full text
    Article
  4. 4
    Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment
    by A. V. Rudakova, E. A. Stadnik
    Published 2020-04-01
    “... from therapy start.The objective of the study was to assess the pharmacoeconomic aspects of therapy...”
    Get full text
    Article
  5. 5
    VACCINATION AGAINST PNEUMOCOCCAL INFECTIONS IN RUSSIAN FEDERATION: SOCIAL AND PHARMACOECONOMIC ASPECTS
    “... and pharmacoeconomic aspects of PCV13 vaccination of 65-year-old patients with various risks of pneumococcal...”
    Get full text
    Article
  6. 6
    Vaccination against Pneumococcal Infections of High-Risk People: Pharmacoeconomic Aspects
    by A. V. Rudakova, S. M. Kharit, Yu. V. Lobzin
    Published 2020-01-01
    “... of the work was to assess the pharmacoeconomic aspects of vaccination of 65 year olds with a high risk...”
    Get full text
    Article
  7. 7
    PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
    by A. V. Rudakova
    Published 2015-09-01
    “... was to describe pharmacoeconomic aspects of using apixaban for stroke and other cardiovascular events prevention...”
    Get full text
    Article
  8. 8
    PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
    by A. V. Rudakova
    Published 2015-09-01
    “... was to describe pharmacoeconomic aspects of using apixaban for stroke and other cardiovascular events prevention...”
    Get full text
    Article
  9. 9
    PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT
    by A. V. Rudakova
    Published 2015-09-01
    Get full text
    Article
  10. 10
    PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY
    by A. V. Rudakova, M. S. Berezhnova
    Published 2015-12-01
    Get full text
    Article
  11. 11
    PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY
    by A. V. Rudakova, M. S. Berezhnova
    Published 2015-12-01
    Get full text
    Article
  12. 12
    PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT
    by A. V. Rudakova
    Published 2015-09-01
    Get full text
    Article
  13. 13
    PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION
    Get full text
    Article
  14. 14
    COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS
    by A. V. Rudakova
    Published 2015-03-01
    Get full text
    Article
  15. 15
    THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE
    by G. E. Ulrikh, A. V. Rudakova
    Published 2017-03-01
    Get full text
    Article
  16. 16
    ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    by A. V. Rudakova
    Published 2015-09-01
    “... period and by the pharmacoeconomic model developed by Pharmerit International (Rotterdam, Netherlands...”
    Get full text
    Article
  17. 17
    ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    by A. V. Rudakova
    Published 2015-09-01
    “... of the health care budget with 5 year horizon period and by the pharmacoeconomic model developed by Pharmerit...”
    Get full text
    Article
Search Tools: Get RSS Feed — Email this Search